tiprankstipranks
Trending News
More News >
Amylyx Pharmaceuticals, Inc. (AMLX)
:AMLX
US Market
Advertisement

Amylyx Pharmaceuticals Inc (AMLX) Stock Forecast & Price Target

Compare
620 Followers
See the Price Targets and Ratings of:

AMLX Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Amylyx
Pharmaceuticals Inc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AMLX Stock 12 Month Forecast

Average Price Target

$13.00
▲(30.65% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Amylyx Pharmaceuticals Inc in the last 3 months. The average price target is $13.00 with a high forecast of $17.00 and a low forecast of $10.00. The average price target represents a 30.65% change from the last price of $9.95.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","18":"$18","4.5":"$4.5","13.5":"$13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.5,9,13.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.72,8.433846153846154,9.147692307692308,9.861538461538462,10.575384615384616,11.28923076923077,12.003076923076923,12.716923076923077,13.430769230769231,14.144615384615385,14.858461538461539,15.572307692307692,16.286153846153848,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.72,8.126153846153846,8.532307692307691,8.938461538461539,9.344615384615384,9.750769230769231,10.156923076923077,10.563076923076924,10.96923076923077,11.375384615384615,11.781538461538462,12.18769230769231,12.593846153846155,{"y":13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.72,7.895384615384615,8.07076923076923,8.246153846153845,8.42153846153846,8.596923076923076,8.772307692307692,8.947692307692307,9.123076923076923,9.298461538461538,9.473846153846154,9.649230769230769,9.824615384615385,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.72,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.64,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.14,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.41,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$17.00Average Price Target$13.00Lowest Price Target$10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on AMLX
Mizuho Securities
Mizuho Securities
$8$12
Buy
20.60%
Upside
Reiterated
08/29/25
Mizuho Securities Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)Mizuho analyst Graig Suvannavejh raised the price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) to $12.00 (from $8.00) while maintaining a Outperform rating.
Bank of America Securities Analyst forecast on AMLX
Bank of America Securities
Bank of America Securities
$10$14
Buy
40.70%
Upside
Reiterated
08/28/25
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (NASDAQ: MLYS), Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) and Veeva Systems (NYSE: VEEV)We reiterate our Buy rating on AMLX and raise our PO to $14 (from $10)
Guggenheim
$17
Buy
70.85%
Upside
Reiterated
08/27/25
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Cooper Co (NASDAQ: COO) and Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)We maintain our high conviction in avexitide's pivotal Phase 3 LUCIDITY enrollment completion by YE2025 with topline data expected in 1H26.
Goldman Sachs Analyst forecast on AMLX
Goldman Sachs
Goldman Sachs
$10
Buy
0.50%
Upside
Reiterated
08/27/25
Goldman Sachs Sticks to Its Buy Rating for Amylyx Pharmaceuticals Inc (AMLX)
H.C. Wainwright Analyst forecast on AMLX
H.C. Wainwright
H.C. Wainwright
$16
Buy
60.80%
Upside
Reiterated
08/08/25
Promising Market Potential and Financial Outlook for Amylyx Pharmaceuticals Inc. Driven by Avexitide's AdvancementsValuation and Risks. Our price target of $16 is based on an equally weighted composite of: (a) $18.49/ share, as a 20x multiple of taxed and diluted 2034 EPS of $2.56/share discounted back to and (b) an NPV discounted cash flow between 2025-2034 of $13/share, with a discount rate of 11% and growth rate of 2%. These assumptions are in line with the expected P/E multiple and discount rates of an early developmental-stage biopharmaceutical company.
Leerink Partners Analyst forecast on AMLX
Leerink Partners
Leerink Partners
$10
Buy
0.50%
Upside
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) and Cormedix (NASDAQ: CRMD)We remain bullish on the avexitide data next year and that is where we think investors should remain focused. However, we look forward to the unblinded Phase 1b PSP data and the early data from the ALS program in 2025, which both have good risk/reward opportunity, given the minimal if any expectations in the investment community. We reiterate our Outperform rating and $10 PT.
TD Cowen Analyst forecast on AMLX
TD Cowen
TD Cowen
Buy
Reiterated
08/07/25
Promising Future for Amylyx Pharmaceuticals: Buy Rating Backed by Avexitide's Market Potential
Citi
$12
Buy
20.60%
Upside
Reiterated
07/14/25
Citi Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)
Robert W. Baird Analyst forecast on AMLX
Robert W. Baird
Robert W. Baird
$3$11
Buy
10.55%
Upside
Upgraded
11/18/24
Strong Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising Avexitide Prospects and Stable Financial Standing
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on AMLX
Mizuho Securities
Mizuho Securities
$8$12
Buy
20.60%
Upside
Reiterated
08/29/25
Mizuho Securities Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)Mizuho analyst Graig Suvannavejh raised the price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) to $12.00 (from $8.00) while maintaining a Outperform rating.
Bank of America Securities Analyst forecast on AMLX
Bank of America Securities
Bank of America Securities
$10$14
Buy
40.70%
Upside
Reiterated
08/28/25
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (NASDAQ: MLYS), Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) and Veeva Systems (NYSE: VEEV)We reiterate our Buy rating on AMLX and raise our PO to $14 (from $10)
Guggenheim
$17
Buy
70.85%
Upside
Reiterated
08/27/25
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Cooper Co (NASDAQ: COO) and Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)We maintain our high conviction in avexitide's pivotal Phase 3 LUCIDITY enrollment completion by YE2025 with topline data expected in 1H26.
Goldman Sachs Analyst forecast on AMLX
Goldman Sachs
Goldman Sachs
$10
Buy
0.50%
Upside
Reiterated
08/27/25
Goldman Sachs Sticks to Its Buy Rating for Amylyx Pharmaceuticals Inc (AMLX)
H.C. Wainwright Analyst forecast on AMLX
H.C. Wainwright
H.C. Wainwright
$16
Buy
60.80%
Upside
Reiterated
08/08/25
Promising Market Potential and Financial Outlook for Amylyx Pharmaceuticals Inc. Driven by Avexitide's AdvancementsValuation and Risks. Our price target of $16 is based on an equally weighted composite of: (a) $18.49/ share, as a 20x multiple of taxed and diluted 2034 EPS of $2.56/share discounted back to and (b) an NPV discounted cash flow between 2025-2034 of $13/share, with a discount rate of 11% and growth rate of 2%. These assumptions are in line with the expected P/E multiple and discount rates of an early developmental-stage biopharmaceutical company.
Leerink Partners Analyst forecast on AMLX
Leerink Partners
Leerink Partners
$10
Buy
0.50%
Upside
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) and Cormedix (NASDAQ: CRMD)We remain bullish on the avexitide data next year and that is where we think investors should remain focused. However, we look forward to the unblinded Phase 1b PSP data and the early data from the ALS program in 2025, which both have good risk/reward opportunity, given the minimal if any expectations in the investment community. We reiterate our Outperform rating and $10 PT.
TD Cowen Analyst forecast on AMLX
TD Cowen
TD Cowen
Buy
Reiterated
08/07/25
Promising Future for Amylyx Pharmaceuticals: Buy Rating Backed by Avexitide's Market Potential
Citi
$12
Buy
20.60%
Upside
Reiterated
07/14/25
Citi Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)
Robert W. Baird Analyst forecast on AMLX
Robert W. Baird
Robert W. Baird
$3$11
Buy
10.55%
Upside
Upgraded
11/18/24
Strong Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising Avexitide Prospects and Stable Financial Standing
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amylyx Pharmaceuticals Inc

1 Month
xxx
Success Rate
9/18 ratings generated profit
50%
Average Return
+1.21%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +1.21% per trade.
3 Months
xxx
Success Rate
11/18 ratings generated profit
61%
Average Return
+23.47%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +23.47% per trade.
1 Year
Andrew FeinH.C. Wainwright
Success Rate
14/20 ratings generated profit
70%
Average Return
+61.63%
reiterated a buy rating 30 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +61.63% per trade.
2 Years
xxx
Success Rate
14/20 ratings generated profit
70%
Average Return
+128.78%
reiterated a xxx
rating 30 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +128.78% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMLX Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
4
8
10
9
6
Buy
0
1
1
7
11
Hold
7
9
7
9
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
18
18
25
27
In the current month, AMLX has received 17 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. AMLX average Analyst price target in the past 3 months is 13.00.
Each month's total comprises the sum of three months' worth of ratings.

AMLX Financial Forecast

AMLX Earnings Forecast

Next quarter’s earnings estimate for AMLX is -$0.46 with a range of -$0.53 to -$0.37. The previous quarter’s EPS was -$0.46. AMLX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year AMLX has Outperformed its overall industry.
Next quarter’s earnings estimate for AMLX is -$0.46 with a range of -$0.53 to -$0.37. The previous quarter’s EPS was -$0.46. AMLX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year AMLX has Outperformed its overall industry.

AMLX Sales Forecast

Next quarter’s sales forecast for AMLX is $52.00K with a range of $0.00 to $416.00K. The previous quarter’s sales results were $0.00. AMLX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year AMLX has Outperformed its overall industry.
Next quarter’s sales forecast for AMLX is $52.00K with a range of $0.00 to $416.00K. The previous quarter’s sales results were $0.00. AMLX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year AMLX has Outperformed its overall industry.

AMLX Stock Forecast FAQ

What is AMLX’s average 12-month price target, according to analysts?
Based on analyst ratings, Amylyx Pharmaceuticals, Inc.’s 12-month average price target is 13.00.
    What is AMLX’s upside potential, based on the analysts’ average price target?
    Amylyx Pharmaceuticals, Inc. has 30.65% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AMLX a Buy, Sell or Hold?
          Amylyx Pharmaceuticals, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Amylyx Pharmaceuticals, Inc.’s price target?
            The average price target for Amylyx Pharmaceuticals, Inc. is 13.00. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $17.00 ,the lowest forecast is $10.00. The average price target represents 30.65% Increase from the current price of $9.95.
              What do analysts say about Amylyx Pharmaceuticals, Inc.?
              Amylyx Pharmaceuticals, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of AMLX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis